Zhang Ning, Komine-Kobayashi Miki, Tanaka Ryota, Liu Meizi, Mizuno Yoshikuni, Urabe Takao
Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Tokyo 113-0033, Japan.
Stroke. 2005 Oct;36(10):2220-5. doi: 10.1161/01.STR.0000182241.07096.06. Epub 2005 Sep 15.
Oxidative stress contributes to ischemia/reperfusion neuronal damage in a consecutive 2-phase pattern: an immediate direct cytotoxic effect and subsequent redox-mediated inflammatory insult. The present study was designed to assess the neuroprotective mechanisms of edaravone, a novel free radical scavenger, through antioxidative and anti-inflammatory pathways, from the early period to up to 7 days after ischemia/reperfusion in mice.
Mice were subjected to 60-minute ischemia followed by reperfusion. They were divided into the edaravone group (n=72; with different schedules for first administration) and the vehicle (control) group (n=36). Infarct volume and neurological deficit scores were evaluated at several time points after ischemia. Immunohistochemical analysis for 4-hydroxy-2-nonenal (HNE), 8-hydroxy-deoxyguanosine (8-OHdG), ionized calcium-binding adapter molecule 1 (Iba-1), inducible NO synthase (iNOS), and nitrotyrosine were performed at 24 hours, 72 hours, or 7 days after reperfusion.
Edaravone, even when administrated 6 hours after onset of ischemia/reperfusion, significantly reduced the infarct volume (68.10+/-6.24%; P<0.05) and improved the neurological deficit scores (P<0.05) at 24 hours after reperfusion. Edaravone markedly suppressed the accumulation of HNE-modified protein and 8-OHdG at the penumbra area during the early period after reperfusion (P<0.05) and reduced microglial activation, iNOS expression, and nitrotyrosine formation at the late period.
Our results indicated that edaravone exerts an early neuroprotective effect through the early free radicals scavenging pathway and a late anti-inflammatory effect and suggested that edaravone is important for expansion of the therapeutic time window in stroke patients.
氧化应激以连续的两阶段模式导致缺血/再灌注神经元损伤:即刻的直接细胞毒性作用以及随后的氧化还原介导的炎症损伤。本研究旨在评估新型自由基清除剂依达拉奉通过抗氧化和抗炎途径,在小鼠缺血/再灌注后早期至7天期间的神经保护机制。
小鼠经历60分钟缺血后再灌注。将它们分为依达拉奉组(n = 72;首次给药有不同方案)和溶剂对照组(n = 36)。在缺血后的几个时间点评估梗死体积和神经功能缺损评分。在再灌注后24小时、72小时或7天进行4-羟基-2-壬烯醛(HNE)、8-羟基脱氧鸟苷(8-OHdG)、离子钙结合衔接分子1(Iba-1)、诱导型一氧化氮合酶(iNOS)和硝基酪氨酸的免疫组织化学分析。
依达拉奉即使在缺血/再灌注开始后6小时给药,在再灌注后24小时也显著减小了梗死体积(68.10±6.24%;P<0.05)并改善了神经功能缺损评分(P<0.05)。依达拉奉在再灌注后的早期显著抑制了半暗带区域HNE修饰蛋白和8-OHdG的积累(P<0.05),并在后期减少了小胶质细胞活化、iNOS表达和硝基酪氨酸形成。
我们的结果表明依达拉奉通过早期自由基清除途径发挥早期神经保护作用,并具有后期抗炎作用,提示依达拉奉对扩大脑卒中患者的治疗时间窗具有重要意义。